We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The addition to yet another set of important clinical guidelines highlights the value BRILINTA can bring to patients with ACS and health care professionals trying to reduce the rate of thrombotic cardiovascular events and the momentum this important treatment option is gaining just four months after FDA approval.”
“The latest guidelines recommend additional use of IVUS and FFR, both of which represent key product lines in Volcano's broad portfolio of precision guided technologies, in patients undergoing PCI. These recommendations confirm the positive role that IVUS and FFR technologies play in the care of PCI patients.”
No takes yet. Share an insight, caveat, or question.
Levine et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: